{
	"kihkd5d3Text": "Bri<span class=\"_ _1\"></span>ntel<span class=\"_ _1\"></span>lix<span class=\"_ _1\"></span>® del<span class=\"_ _1\"></span>iv<span class=\"_ _1\"></span>ers ef<span class=\"_ _4\"></span>fec<span class=\"_ _4\"></span>tiv<span class=\"_ _1\"></span>e and s<span class=\"_ _1\"></span>us<span class=\"_ _4\"></span>tai<span class=\"_ _1\"></span>ned re<span class=\"_ _1\"></span>lief <br><span class=\"ls20 ws29\">fr<span class=\"_ _0\"></span>om symptoms of<span class=\"_ _4\"></span> MDD<span class=\"_ _1\"></span>*<span class=\"fs3 ls1e ws26 v1\">1-3</span></span>",
	"kihkd5d4Text": "Study Design",
	"kihkd5d5Text": "Brintellix® significantly improved depr<span class=\"_ _1\"></span>essive symptoms with a similar <br>effect size vs.<span class=\"_ _1\"></span> placebo as venlafaxine*<span class=\"fs5 v2\">2</span>",
	"kihkd5d6Text": "Change in MADRS total score<span class=\"fs8 v4\">2</span>",
	"kihkd5d7Text": "MADRS mean change  <span class=\"_ _48\"></span>from baseline",
	"kihkd5d8Text": "<font style=\"font-size: 17px;\"><div style=\"text-align: center;\">T<span class=\"_ _1\"></span>re<span class=\"_ _0\"></span>atment week</div></font>",
	"kihkd5d9Text": "<div style=\"text-align: center;\">P<span class=\"_ _1\"></span>rimary</div><div style=\"text-align: center;\">endpoint<br></div>",
	"kihkd5dbText": "<div style=\"text-align: center;\">LOCF</div><div style=\"text-align: center;\">endpoint</div>",
	"kihkd5dgText": "Efficacy without ",
	"kihkd5dhText": "compromising ",
	"kihkd5diText": "tolerability**",
	"Brintellix_24ac292f45": "<span style=\"color: rgb(77, 127, 134); font-family: '15_VDWFON+AvenirNextLTPro-Demi';\"><font style=\"font-size: 25px;\">References</font></span>",
	"Brintellix_243fcdaed8": "<font style=\"font-size: 15px; font-family: '2_VDWFON+AvenirNextLTPro-Demi'; color: rgb(100, 94, 94);\"><b>1.<br>2.<br>3.<br><br></b></font>",
	"Brintellix_244994b318": "<font style=\"font-size: 15px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';color: rgb(100, 94, 94);\">Katona C et al. Int Clin Pyschopharmacol 2012;27:215-223.<br>Alvarez E et al. Int J Neuropsychopharmacol 2012;15:589-600.<br>Vieta E et al. Eur Neuropsychopharmacol 2017;27:877-884.<br><br></font>",
	"Brintellix_2428145f2f": "<font style=\"font-size: 14px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';\">Placebo (n=105)</font>",
	"Brintellix_2436a0eee0": "<font style=\"font-size: 14px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';\">Venlafaxine 225 mg (n=112)<br>(active reference)</font>",
	"Brintellix_24294f903d": "<font style=\"font-size: 14px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';\">Brintellix<sup style=\"line-height:0;\">®</sup> 5 mg (n=108)</font>",
	"Brintellix_245c37eb79": "<font style=\"font-size: 14px; font-family: '3_BNJCUB+AvenirNextLTPro-Regular';\">Brintellix<sup style=\"line-height:0;\">®</sup> 10 mg (n=100)</font>",
	"Brintellix_241f348ac7": "<div style=\"line-height: 1;\"><div style=\"\"><font style=\"font-size: 11px;line-height:1.3; font-family: &quot;3_BNJCUB+AvenirNextLTPro-Regular&quot;;\">*As assessed by MADRS at Week 6.\n\t<br>**p<0.05; ***p<0.01; †p<0.001 vs. placebo. In a randomised, double-blind placebo-controlled, active-referenced study in adult patients with\n\t<br>severe MDD, as defined by a MADRS total score of ≥30.\n\t<br>Brintellix<sup>®</sup> was significantly superior to placebo in change from baseline in MADRS total scores (primary efficacy endpoint) at Week 6 (LOCF).\n\t<br>The statistical model was an analysis of covariance (ANCOVA). The primary efficacy analysis, evaluated using MADRS, was repeated on\n\t<br>observed case data using both ANCOVA and MMRM. Brintellix<sup>®</sup> (5 mg or 10 mg) and venlafaxine (225 mg) were all significantly superior to\n\t<br>placebo as assessed by MADRS at Week 6. Venlafaxine was included as active reference for study validation, not for comparison of effect size.\n\t<br><sup>‡</sup>Brintellix<sup>®</sup> does not exhibit many of the side effects typical of SSRIs and SNRIs including sexual dysfunction and weight gain. 5-8 Side effects\n\t<br>associated with Brintellix<sup>®</sup> were compared with those of the SSRIs escitalopram and paroxetine and with those of the SNRI venlafaxine. For\n\t<br>the 20 mg/day dose, an increase in treatment-emergent sexual dysfunction was seen compared to placebo. Please refer to the full Summary\n\t<br>of Product Characteristics or Prescribing Information for further information on safety and tolerability.\n\t<br>LOCF, last observation carried forward; MADRS, Montgomery-Åsberg depression rating scale; MMRM, mixed model for repeated\n\t<br>measurements.\n\t<br></font></div></div>",
	"Brintellix_248e3766ca": "",
	"Brintellix_245ee89fa6": "",
	"Brintellix_2499207ee9": "",
	"Brintellix_2421f47f04": "Text",
	"Brintellix_24f360d728": "Text",
	"Brintellix_249e01b815": "Text",
	"Brintellix_24e4ca1dd5": "Text",
	"Brintellix_24461020c7": "Text",
	"Brintellix_24be9b50bc": "Text",
	"Brintellix_24bd27dec0": "<div style=\"font-family: serif;font-family: '2_VDWFON+AvenirNextLTPro-Demi';font-size: 13px;background-color: #e5f0f2;box-sizing: border-box;color: #4d7f86;\">\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">MADRS 10</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Physical symptoms</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Remission</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Relapse prevention</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;color: #fff;background: rgb(233,90,0);background: linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);background: -webkit-linear-gradient(90deg, rgba(233,90,0,1) 0%, rgba(240,125,0,1) 100%);\">Short term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Long term</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 12px 17px;line-height:1.3;background-color: #e5f0f2;\">Meta-analysis</div>\n\t<div style=\"float: left;text-align: center;border-left: 1px solid #fff;padding: 4px 12px 3px;line-height:1.3;background-color: #e5f0f2;\">Suboptimal responses<br>to SSRI/SNRI</div>\n</div>",
	"Brintellix_24da63a6b3": "Text"
}
